Your session is about to expire
← Back to Search
Nivolumab + Ipilimumab for Liver Cancer (CheckMate 9DW Trial)
CheckMate 9DW Trial Summary
This trial is testing a new combination therapy for liver cancer compared to the current standard of care. The goal is to see if the new therapy can improve survival rates.
CheckMate 9DW Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCheckMate 9DW Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.CheckMate 9DW Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My condition is advanced liver cancer.I have had severe liver-related brain issues in the last year.My liver cancer is of a specific rare type.There are other requirements that need to be met which are described in the study's guidelines.I have active cancer spread to my brain or its coverings.My liver cancer diagnosis was confirmed through a tissue sample.My liver function is slightly impaired.I am fully active or restricted in physically strenuous activity but can do light work.I have at least one measurable tumor that has not been treated.I have had a liver transplant.
- Group 1: Sorafenib/lenvatinib
- Group 2: Nivolumab + Ipilimumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Could you tell me if Nivolumab is certified by the FDA?
"Nivolumab is classified as safe due to evidence from Phase 3 trials, which are large-scale studies that show the drug's efficacy and safety."
What is Nivolumab's efficacy in previous clinical trials?
"There are 1002 active clinical trials studying the effects of Nivolumab. Of these, 137 have reached Phase 3. Most research centres for Nivolumab are located in Pittsburgh, however there are 49831 sites running clinical trials related to Nivolumab worldwide."
Is there still space available in this trial for willing participants?
"Unfortunately, this particular trial is not currently recruiting. The listing was created on September 30th 2019 but the most recent update occurred on October 27th, 2022. There are presently 2690 studies actively enrolling patients with carcinoma and 1002 studies for Nivolumab that seeking participants."
Is this research being conducted in various locations around the city?
"Currently, this clinical trial is enrolling patients at the following locations: Rutgers, New jersey Medical School in Newark, New Jersey; Rutgers University New Jersey Medical School in Edmonton, Alberta; and Alberta Health Services in Ann Arbor, Michigan. In addition, there are 5 other sites where recruitment is taking place."
What are the main conditions that Nivolumab has been FDA approved to target?
"Nivolumab is a common choice for treating unresectable melanoma. Nivolumab has also been shown to be effective in managing squamous cell carcinoma, high risk of recurrence, and disease."
Share this study with friends
Copy Link
Messenger